Hofseth BioCare ASA (HBC) Fair Value & Analysis
Consumer Defensive · NO · Market cap 651M NOK
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 52 days ago
Share price −8.6% over the past month.
Below-average quality, screening 71% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (kr 1.70). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range kr 1.12 – kr 8.30 · fair‑value band kr 1.70 – kr 2.84 · the kr 1.33 price screens below the kr 2.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 23, 2026.
Analysis
Hofseth BioCare ASA (HBC) currently trades at kr 1.33, while our model-based Fair Value estimate is kr 2.27, implying the stock looks roughly 70.7% undervalued today. The Quality Score stands at 34/100 (below-average quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Hofseth BioCare ASA generated revenue of 256M NOK at a net margin of -52.6%. Revenue grew 11.2% year over year. Net debt stands at 191M NOK. Fundamentals as of Jun 23, 2026
Our scenario range runs from kr 1.70 (bear case) to kr 2.84 (bull case); at kr 1.33, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -14% fair-value upside, at 71%, HBC screens cheaper than that median.
Notify me when HBC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States.
Full company description
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hofseth BioCare ASA reported revenue of kr 256M in FY2025 versus kr 87.6M in FY2021, a compound +30.8%/yr. Reported net income was −kr 135M in FY2025.
Watch HBC: get an alert when its fair value changes →
Peer Group
Packaged Foods · 652 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaged Foods median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé India Limited NESTLEIND | ₹1,507 | ₹362.37 | -76% |
| Britannia Industries Limited BRITANNIA | ₹5,646 | ₹1,870 | -67% |
| Tata Consumer Products Limited TATACONSUM | ₹1,062 | ₹327.27 | -69% |
| PT Indofood CBP Sukses Makmur Tbk ICBP | 7,550 IDR | 12,864 IDR | +70% |
| Samyang Foods Co 003230 | 1,219,000 KRW | 1,010,543 KRW | -17% |
| Patanjali Foods Limited PATANJALI | ₹352.60 | ₹144.77 | -59% |
| Vietnam Dairy Products Joint Stock Company VNM | 61,600 VND | 52,858 VND | -14% |
| PT Mayora Indah Tbk, MYOR | 1,665 IDR | 2,699 IDR | +62% |
| PT Cisarua Mountain Dairy Tbk CMRY | 4,630 IDR | 4,350 IDR | -6% |
| Nongshim Co 004370 | 389,500 KRW | 530,619 KRW | +36% |
Compare Hofseth BioCare ASA with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Hofseth BioCare ASA (HBC) overvalued or undervalued?
What is the fair value of HBC?
What is the quality score of HBC?
What is the revenue of Hofseth BioCare ASA (HBC)?
What is the net profit margin of HBC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hofseth BioCare ASA and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.